ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

Biotechnology Healthcare San Diego, CA, United States SPRY (NGM)

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has ARS Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for ARS Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does ARS Pharmaceuticals, Inc. have?
ARS Pharmaceuticals, Inc. has approximately 162 employees.
What industry is ARS Pharmaceuticals, Inc. in?
ARS Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is ARS Pharmaceuticals, Inc. a publicly traded company?
Yes, ARS Pharmaceuticals, Inc. is publicly traded under the ticker symbol SPRY on the NGM. The company has a market capitalization of approximately $1.12 billion.
Where is ARS Pharmaceuticals, Inc. headquartered?
ARS Pharmaceuticals, Inc. is headquartered in San Diego, CA, United States at 11682 El Camino Real, San Diego, CA 92130, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.